リコンビナント
RabMAb

Anti-PD-L1 抗体 [SP142] - C-terminal, prediluted (ab228463)

ab228463 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab228463 は 21 報の論文で使用されています。

  • Zacharakis N  et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24:724-730 (2018). PubMed: 29867227
  • Parra ER  et al. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93 (2018). PubMed: 28719380
  • Wang L  et al. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol 71:20-29 (2018). PubMed: 28782638
  • Shao L  et al. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 9:249-258 (2017). PubMed: 28721097
  • Thompson ED  et al. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol 30:1551-1560 (2017). PubMed: 28731046
  • Joneja U  et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol 70:255-259 (2017). PubMed: 27531819
  • Jin S  et al. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget 8:38850-38862 (2017). PubMed: 28418918
  • Lai AZ  et al. Detection of anALKFusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist 22:774-779 (2017). PubMed: 28507204
  • Alvi MA  et al. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer 117:203-209 (2017). PubMed: 28595259
  • Imai D  et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 6:1614-1626 (2017). PubMed: 28602029
  • Reddy OL  et al. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol 12:45 (2017). PubMed: 28623908
  • Colombo C  et al. ß-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Mol Oncol 11:1495-1507 (2017). PubMed: 28627792
  • Momose K  et al. MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. Oncol Lett 14:958-964 (2017). PubMed: 28693258
  • Falchook GS  et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 4:70 (2016). PubMed: 27879972
  • McDermott DF  et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol 34:833-42 (2016). PubMed: 26755520
  • Melosky B  et al. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. J Clin Oncol 34:1676-88 (2016). PubMed: 26884577
  • Ilie M  et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 468:511-25 (2016). PubMed: 26915032
  • Shi L  et al. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res 22:1173-1184 (2016). PubMed: 26933175
  • Böhm S  et al. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. Clin Cancer Res 22:3025-36 (2016). PubMed: 27306793
  • Garber ST  et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18:1357-66 (2016). PubMed: 27370400
  • Vieira T  et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 98:51-58 (2016). PubMed: 27393506

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録